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Diabetes mellitus is a serious and growing health problem worldwide and is associated with severe acute and chronic complica-
tions. Moreover, epidemiologic evidence suggests that people with diabetes are at significantly higher risk for many forms of can-
cer. Several studies indicate an association between diabetes and the risk of liver, pancreas, endometrium, colon/rectum, breast, 
and bladder cancer. Mortality is also moderately increased in subjects with diabetes. Common risk factors such as age, obesity, 
physical inactivity and smoking may contribute to increased cancer risk in diabetic patients. Hyperinsulinemia most likely favors 
cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic as well as mitogenic effects, and its action in 
malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. The effect of diabetes treatment 
drugs, aside from metformin, on cancer is not conclusive. In order to fight the perfect storm of diabetes and cancer, strategies to 
promote primary prevention and early detection of these conditions are urgently needed.
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INTRODUCTION
Diabetes mellitus (DM) is a serious and growing health prob-
lem worldwide and is associated with severe acute and chronic 
complications. Today, 250 million people live with diabetes glob-
ally, and this figure is expected to reach 366 million in 2030 [1]. 
Therefore, if diabetes is associated with an increase in the risk 
of cancer, this may have a tremendous impact on health world-
wide. The industrialization and economic growth accompanied 
by the so-called ‘westernization’ of lifestyle, characterized by a 
high-calorie diet, obesity, and physical inactivity may explain 
this diabetes epidemic. As a result of this change, the mortality 
of lifestyle-related diseases such as cancer, diabetes, and cardio-
vascular disease has increased in many countries including 
South Korea. Worldwide, cancer is the 2nd and diabetes is the 
12th leading cause of death [2]. According to the recent Statis-
tics Korea report for 2009 [3], cancer is the leading cause of 
death and DM is the 5th most common cause of death. 
  Epidemiologic evidence suggests that people with diabetes 
are at significantly higher risk for many forms of cancer [4-7]. 
Park et al. [8] found that death by malignancy was markedly 
increased (from 4.7% to 21.9%) in Korean type 2 diabetes pa-
tients during the past 10 years. Type 2 diabetes and cancer share 
many risk factors, but potential biologic links between the two 
diseases are not completely understood. 
  In this review, we will discuss Korean and foreign evidences 
of an association between diabetes and cancer, and the possi-
ble mechanisms involved. The link between diabetes treatment 
and cancer risk will also be reviewed.
INCREASED CANCER INCIDENCE IN 
DIABETIC PATIENTS
Many longitudinal and case-control studies, often pooled in 
meta-analyses, have explored the association between diabetes 
and a large array of different neoplasms. Recently, the results 
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of several studies have been combined for a meta-analytic study 
[4,9] and the results are shown in Table 1. The relative risks im-
parted by diabetes are greatest (about twofold or higher) for can-
cers of the liver, pancreas, and endometrium, and lesser (about 
1.2 to 1.5 fold) for cancers of the colon and rectum, breast, and 
bladder. Other cancers (such as lung) do not appear to be asso-
ciated with diabetes, and the evidence for some (e.g., kidney, 
non-Hodgkin’s lymphoma) is inconclusive. Diabetes is associ-
ated with a lower risk of prostate cancer only. 
  Previous meta-analyses are mainly derived from Western 
populations. However, a 10-year prospective cohort study of 
1.3 million Koreans aged 30 to 95 years [10] found that cancer 
incidence is generally elevated for persons with diabetes or an 
elevated fasting serum glucose level greater than 125 mg/dL 
(6.9 mmol/L) compared with those without hyperglycemia. The 
association was strongest for pancreatic cancer, comparing the 
highest and lowest strata in men (hazard ratio [HR], 1.91; 95% 
confidence interval [CI], 1.52 to 2.41) and in women (HR, 2.05; 
95% CI, 1.43 to 2.93). Significant associations were also found 
for cancers of the esophagus, liver, and colon/rectum in men and 
of the liver and cervix in women. There were also significant 
trends with glucose level and cancers of the esophagus, colon/
rectum, liver, pancreas, and bile duct in men and of the liver 
and pancreas in women. We also have reported that 30% of 
pancreatic cancer patients have diabetes [11]. Findings similar 
to those of the Korean cohort study were seen in the Japan Pu-
bic Health Center-based Prospective (JPHC) study of 110,000 
Japanese aged 40 to 60 years [12]. 
  The large majority of the epidemiologic data on cancer inci-
dence and mortality has been obtained from type 2 diabetic 
patients. Because of the different physiology between the two 
subtypes of diabetes, these findings cannot be extended to type 
1 diabetic patients. However, the risk of cancer among patients 
with type 1 diabetes (T1DM) has been investigated in two co-
hort studies. A Swedish study of over 29,000 T1DM patients 
revealed an overall 20% increase in the risk of cancer [13]. In 
particular, the risks of stomach, uterine cervix, and endome-
trium neoplasm were almost doubled. A UK study involving 
28,900 individuals showed that the risk of ovarian cancer and 
the mortality associated with this neoplasm was more than two-
fold higher in subjects with T1DM than in controls [14]. No 
other significant associations were found.
INCREASED CANCER MORTALITY IN 
DIABETIC PATIENTS
Besides its role as an independent risk factor for the develop-
ment of several tumors, diabetes can also have impact on can-
cer prognosis. Several studies have documented increased can-
cer mortality in subjects with diabetes. A recent meta-analysis 
of 23 studies comparing overall survival in cancer patients with 
and without preexisting diabetes showed that diabetes was as-
sociated with an increased mortality HR of 1.41 (95% CI, 1.28 
to 1.55) compared with normoglycemic individuals across all 
cancer types [15]. Subgroup analyses by cancer type showed an 
increased risk for cancers of the endometrium (HR, 1.76; 95% 
CI, 1.34 to 2.31), breast (HR, 1.61; 95% CI, 1.46 to 1.78), and 
colorectum (HR, 1.32; 95% CI, 1.24 to 1.41). A cohort study 
including Korean individuals [10] of both genders revealed a 
linear trend of increasing mortality with increasing fasting se-
rum glucose levels, even in the non-diabetic range. The linear 
association between fasting serum glucose levels and cancer 
mortality was particularly evident for malignancies of the pan-
creas, colon/rectum, liver, esophagus, and biliary tract among 
men and the pancreas, liver, and uterine cervix in women.
Table 1. Meta-analysis on the relative risk (RR) for cancer in 
different origins of diabetic patients (Modified from Vigneri P, 
et al. Endocr Relat Cancer 2009;16:1103-23, with permission 
from Society for Endocrinology) [4]
Cancer origin Analyzed studies RR (95% CI)
Liver 13 case-control studies
7 cohort studies
2.50 (1.8-3.5)
2.51 (1.9-3.2)
Pancreas 17 case-control studies
19 cohort studies
1.94 (1.53-2.46)
1.73 (1.59-1.88)
Kidney
 a 1 cohort study
1 cohort study
1.50 (1.30-1.70)
2.22 (1.04-4.70)
Endometrium 13 case-control studies
3 cohort studies
2.22 (1.80-2.74)
1.62 (1.21-2.16)
Colon/rectum 6 case-control studies
9 cohort studies
1.36 (1.23-1.50)
1.29 (1.16-1.43)
Bladder 7 case-control studies
3 cohort studies
1.37 (1.04-1.80)
1.43 (1.18-1.74)
Non-Hodgkin’s  
   lymphoma
11 case-control studies
5 cohort studies
1.12 (0.95-1.31)
1.41 (1.07-1.88)
Breast 5 case-control studies
15 cohort studies
1.18 (1.05-1.32)
1.20 (1.11-1.30)
Prostate 9 case-control studies
10 cohort studies
0.89 (0.72-1.11)
0.81 (0.71-0.92)
CI, confidence interval.
aKidney cancer data was not obtained from meta-analysis. 195
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COMMON RISK FACTORS FOR BOTH 
CANCER AND DIABETES
Diabetes and cancer represent common health concerns, and 
they often coexist in the same individuals. Overall, 8% to 18% 
of individuals suffering from cancer also have diabetes, and 
prevalence rates vary according to tumor sites [16]. 
Age
Over 60% of cancer diagnoses are made in individuals aged 65 
years or more [17]; since the prevalence of diabetes reaches 17% 
in this age class, the coexistence of diabetes and cancer is des-
tined to raise as life expectancy increases. 
Obesity
Type 2 diabetes is strongly related to overweight and obesity, 
two conditions associated with an increased risk of several can-
cers [18]. Cancers most consistently associated with overweight 
and obesity are breast (in postmenopausal women), colon/rec-
tum, endometrium, pancreas, adenocarcinoma of the esopha-
gus, kidney, gallbladder, and liver. Moreover, obesity is associ-
ated with higher cancer incidence and mortality [19,20].
Physical inactivity
Evidence from observational epidemiologic studies consistent-
ly shows that higher levels of physical activity are associated 
with a lower risk of the colon, postmenopausal breast, and en-
dometrial cancer [21,22]. Prevention of diabetes with increased 
physical activity has been proven by numerous trials [23-26].
Smoking
It is estimated that worldwide, cigarette smoking accounts for 
71% of all trachea, bronchus, and lung cancer deaths [27]. Oth-
er cancers strongly associated with smoking are cancers of the 
larynx, upper digestive tract, bladder, kidney, pancreas, liver, 
stomach, uterine cervix, and leukemia. Studies suggest that 
smoking is also an independent risk factor for the development 
of diabetes [28,29].
POSSIBLE MECHANISMS UNDERLYING 
DIABETES AND CANCER
The role of insulin in promoting cancer growth was first recog-
nized by studies in experimental animals as early as 1972 [30,31]. 
Diabetes is generally characterized by hyperglycemia and hy-
perinsulinemia, which are often coupled with a reduced meta-
bolic effect of insulin (insulin resistance) in peripheral tissues. 
Chronic hyperinsulinemia, however, is a possible factor favor-
ing cancer initiation and progression in diabetic patients due to 
the mitogenic effect of insulin, which has been reviewed in de-
tail [32]. In brief, an increase in insulin levels leads to a decrease 
in the liver synthesis and blood levels of insulin-like growth fac-
tor binding protein 1 (IGFBP1), and is associated with a decrease 
in IGFBP2 in the blood. These effects in turn result in an in-
crease in bioavailable IGF1. Insulin and IGF1 signal through 
insulin receptors and IGF1 receptors, respectively, to promote 
cellular proliferation and inhibit apoptosis in many tissue types. 
These effects might contribute to cancerogenesis.
  Many cancer cells have increased insulin receptor (IR) con-
tent [33]. In malignant cells, the expression of the isoform (IR-
A) is predominant, and its activation elicits more mitogenetic 
than metabolic effects [34]. By binding to the overexpressed 
IR-A, insulin may favor cancer progression and facilitate the 
growth of tumors that would otherwise have likely remained 
clinically irrelevant.
  Insulin mitogenic activity might be enhanced at the cellular 
level by post-receptor molecular mechanisms, including insu-
lin (or its synthetic analogs) residence time on the receptor [35] 
and the intracellular up-regulation of the insulin mitogenic path-
way.
DIABETES TREATMENT AND CANCER
Most diabetic patients are treated for years or decades with a va-
riety of drugs. The potential role of these drugs in favoring can-
cer is unclear, but is most likely minor, if any. The data are not 
conclusive because the large majority of diabetic patients change 
the drug dosage and/or type many times during the course of 
the disease. Moreover, many are treated with more than one 
drug simultaneously. As a result, this issue is not well-studied 
epidemiologically, and evidence is weak, inconclusive and con-
troversial. The debate about the potential risk of developing 
cancer associated with insulin use has been ignited by the pub-
lication of four observational studies [36-39] in 2009. However, 
randomized clinical trial data from an open-label 5-year trial 
of insulin glargine versus NPH insulin did not find any evidence 
of excess cancer risk with insulin glargine [40]. Due to the meth-
odological limitations of previous studies, which have been 
broadly debated [41-43], a clear relationship between use of 
insulin glargine and increased risk of cancer cannot be estab-196
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lished. 
  On the contrary, a mounting body of evidence suggests that 
metformin may reduce cancer risk [36,44-47] or mortality [48] 
in diabetic patients. There is probably a dual mechanism for 
the anticancer effect of metformin. In addition to the lowering 
of circulating levels of insulin, metformin stimulates expres-
sion of AMPK, leading to the rapid inhibition of cellular pro-
tein synthesis and growth [49,50].
CONCLUSION
Descriptive and analytical evidence obtained to date suggest 
that cancer risk and cancer mortality are increased in diabetic 
patients, providing more evidence for some site-specific can-
cers. The increase in the risk of cancer is likely related to the in-
terplay between obesity, hyperinsulinemia and hyperglycemia. 
Improved glycemic control guidelines with a wide prescription 
of statin and aspirin have reduced death from vascular compli-
cations and diabetes itself. As a result, death by cancer is rising 
steeply although cardiovascular disease and infection are still 
the leading cause of the death. The impressive rate of increase 
in the incidence of both diabetes and obesity will pose serious 
problems to many countries including South Korea. In order 
to fight the perfect storm of diabetes and cancer, preventive 
strategies to promote primary prevention and early detection 
of these conditions are urgently needed.
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